Search Within

Jonathan Eric Rosenberg

Formats
  1. Meeting Abstract (283)
  2. Journal Article (195)
  3. Review (18)
  4. Correspondence (10)
  5. Editorial (5)
  6. Guidelines (4)
  7. Book Section (2)
  8. Research Letter (2)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (520)
  2. Genitourinary Oncology Service (520)
  3. Solid Tumor Oncology Division (520)
  4. Department of Pathology and Laboratory Medicine (149)
  5. Surgery (140)
  6. Urology (137)

More Groups

People
  1. Dean Bajorin (204)
  2. Gopakumar Iyer (175)
  3. Hikmat Al-Ahmadie (134)
  4. Bernard Bochner (124)
  5. David Solit (114)
  6. Min Yuen Teo (75)

More People

Years
  1. 2025 (23)
  2. 2024 (36)
  3. 2023 (32)
  4. 2022 (36)
  5. 2021 (48)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (204)
  2. Annals of Oncology (42)
  3. European Urology (20)
  4. Clinical Genitourinary Cancer (18)
  5. Clinical Cancer Research (16)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (210)
  2. Oxford University Press (47)
  3. Elsevier Inc. (39)
  4. Elsevier Science, Inc. (36)
  5. Nature Publishing Group (36)
  6. American Association for Cancer Research (35)

More Publishers

Results (520)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts)
    Meeting Abstract

    Wei, X. X.; Lundgren, K.; Teo, M. Y.; Rosenberg, J. E.; Koshkin, V. S.; Grivas, P.; Carril, L.; Castellano, D. E.; Velho, P.; Hahn, N. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Rosenberg, J. E.; Sridhar, S. S.; Zhang, J.; Smith, D. C.; Ruether, J. D.; Flaig, T. W.; Baranda, J. C.; Lang, J. M.; Plimack, E. R.; Sangha, R. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy
    Meeting Abstract

    Rosenberg, J. E.; Heath, E. I.; O'Donnell, P. H.; Hahn, N. M.; Balar, A. V.; Gartner, E. M.; Melhem-Bertrandt, A.; Petrylak, D. P.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • DNA damage repair (DDR) germline mutations in patients (Pts) with urothelial carcinoma (UC)
    Meeting Abstract

    Carlo, M. I.; Vijai, J.; Mandelker, D.; Kemel, Y.; Regazzi, A. M.; Zhang, L.; Stadler, Z. K.; Walsh, M. F.; Cadoo, K. A.; Solit, D. B.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210
    Meeting Abstract

    Balar, A. V.; Dreicer, R.; Loriot, Y.; Perez-Gracia, J. L.; Hoffman-Censits, J. H.; Petrylak, D. P.; Van Der Heijden, M. S.; Ding, B.; Shen, X.; Rosenberg, J. E.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Relapse-free survival (RFS) of clinical T2-4N0 urothelial bladder carcinoma (UBC) after radical cystectomy (RC), with or without perioperative chemotherapy (POC): Endpoints for clinical trial design
    Meeting Abstract

    Bandini, M.; Briganti, A.; Plimack, E. R.; Niegisch, G.; Yu, E. Y.; Bamias, A.; Agarwal, N.; Sridhar, S. S.; Sternberg, C. N.; Vaishampayan, U. N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Estimation of tumor-derived mutant allele fractions in cfDNA by shallow whole genome sequencing and fragment size analysis
    Meeting Abstract

    Yang, J.; Marass, F.; Ulz, P.; Shady, M.; Cheng, M. L.; Kothari, P.; Gedvilaite, E.; Somnay, S.; Shukla, N.; Modak, S.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression
    Meeting Abstract

    Rosenberg, J.; Necchi, A.; Sweis, R. F.; Nakajima, K.; Lu, C.; Nogai, H.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy
    Meeting Abstract

    Rosenberg, J. E.; Balar, A.; O'Donnell, P. H.; Heath, E. I.; Hahn, N. M.; Cavazos, N. M.; Melhem-Bertrandt, A.; Petrylak, D. P.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032
    Meeting Abstract

    Rosenberg, J. E.; Sharma, P.; de Braud, F. G. M.; Basso, U.; Calvo, E.; Bono, P.; Morse, M.; Ascierto, P. A.; Lopez-Martin, J. A.; Brossart, P.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save